Heparan sulfate and heparin interactions with proteins

Journal of the Royal Society Interface

Volumn 12, Issue 110, 2015, Pages

  Meneghetti, Maria C Z ^a   Hughes, Ashley J ^b,c   Rudd, Timothy R ^c,d   Nader, Helena B ^a   Powell, Andrew K ^c,e   Yates, Edwin A ^a,c   Lima, Marcelo A ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Cations; Heparan sulfate; Heparin; Polysaccharide; Protein binding; Redundancy

Indexed keywords

BINDING SITES; BIOACTIVITY; BIOCHEMISTRY; CELL MEMBRANES; DNA SEQUENCES; POLYSACCHARIDES; POSITIVE IONS; PROTEINS; REDUNDANCY; SULFUR COMPOUNDS;

EXTRACELLULAR MATRICES; HEPARAN SULFATES; HEPARIN; MULTICELLULAR ANIMALS; MULTIPLE BINDING SITES; PROTEIN BINDING; SEQUENCE SPECIFICITY; STRUCTURE ACTIVITY RELATIONSHIPS;

HYDRAULIC STRUCTURES;

ANTITHROMBIN; CATION; FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN; HEPARIN DERIVATIVE; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; OLIGOSACCHARIDE; PENTASACCHARIDE; POLYANION; POLYSACCHARIDE; PROTEIN; PROTEOHEPARAN SULFATE;

ANGIOGENESIS; BINDING SITE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; EX VIVO STUDY; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; HUMAN; MAST CELL; METABOLISM;

ANIMALS; BINDING SITES; HEPARIN; HEPARITIN SULFATE; HUMANS; MAST CELLS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84942019114     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2015.0589     Document Type: Review

References (162)

1. Perlin AS, Mackie DM, Dietrich CP. 1971 Evidence for a (1!4)-linked 4-O-(-L-idopyranosyluronic acid 2- sulfate)-(2-deoxy-2-sulfoamino-D-glucopyranosyl 6- sulfate) sequence in heparin. Long-range H-H coupling in 4-deoxy-hex-4-enopyranosides. Carbohydr. Res. 18, 185-194. (doi:10.1016/S0008-6215(00)80341-9).
2. Casu B et al. 1996 Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arzneimittelforschung 46, 472-477.
3. Rabenstein DL. 2002 Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 19, 312-331. (doi:10.1039/b100916h).
4. Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP. 1985 Lack of correlation between 'in vitro' and 'in vivo' antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent 'in vivo'. Thromb. Res. 40, 597-607. (doi:10.1016/0049-3848(85)90298-1).
5. Dietrich CP et al. 1998 Structure of heparan sulfate: identification of variable and constant oligosaccharide domains in eight heparan sulfates of different origins. Cell Mol. Biol. (Noisy-le-grand). 44, 417-429.
6. Gallagher JT, Walker A. 1985 Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides. Biochem. J. 230, 665-674.
7. Casu B. 1989 Structure of heparin and heparin fragments. Ann. NY Acad. Sci. 556, 1-17. (doi:10.1111/j.1749-6632.1989.tb22485.x).
8. Rosenberg RD, Lam L. 1979 Correlation between structure and function of heparin. Proc. Natl Acad. Sci. USA 76, 1218-1222. (doi:10.1073/pnas.76.3.1218).
9. Mulloy B, Gray E, Barrowcliffe TW. 2000 Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb. Haemost. 84, 1052-1056.
10. Khan S, Fung KW, Rodriguez E, Patel R, Gor J, Mulloy B, Perkins SJ. 2013 The solution structure of heparan sulfate differs from that of heparin: implications for function. J. Biol. Chem. 288, 27737-27751. (doi:10.1074/jbc.M113.492223).
11. Khan S, Gor J, Mulloy B, Perkins SJ. 2010 Semi-rigid solution structures of heparin by constrained X-ray scattering modelling: new insight into heparin- protein complexes. J. Mol. Biol. 395, 504-521. (doi:10.1016/j.jmb.2009.10.064).
12. Brito AS et al. 2014 A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential. Carbohydr. Polym. 99, 372-378. (doi:10.1016/j.carbpol.2013.08.063).
13. Parra A, Veraldi N, Locatelli M, Fini M, Martini L, Torri G, Sangiorgi L, Bisio A. 2012 Heparin-like heparan sulfate from rabbit cartilage. Glycobiology 22, 248-257. (doi:10.1093/glycob/cwr143).
14. Dietrich CP, Nader HB, Perlin AS. 1975 The heterogeneity of heparan sulfate from beef-lung tissue: p.m.r.-spectral evidence. Carbohydr. Res. 41, 334-338. (doi:10.1016/S0008-6215(00)87036-6).
15. Lyon M, Deakin JA, Gallagher JT. 1994 Liver heparan sulfate structure. A novel molecular design. J. Biol. Chem. 269, 11208-11215.
16. Vongchan P, Warda M, Toyoda H, Toida T, Marks RM, Linhardt RJ. 2005 Structural characterization of human liver heparan sulfate. Biochim. Biophys. Acta 1721, 1-8. (doi:10.1016/j.bbagen.2004.09.007).
17. Nader HB, Dietrich CP, Buonassisi V, Colburn P. 1987 Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc. Natl Acad. Sci. USA 84, 3565-3569. (doi:10.1073/pnas.84.11.3565).
18. Shao C, Shi X, White M, Huang Y, Hartshorn K, Zaia J. 2013 Comparative glycomics of leukocyte glycosaminoglycans. FEBS J. 280, 2447-2461. (doi:10.1111/febs.12231).
19. Stringer SE, Mayer-Proschel M, Kalyani A, Rao M, Gallagher JT. 1999 Heparin is a unique marker of progenitors in the glial cell lineage. J. Biol. Chem. 274, 25455-25460. (doi:10.1074/jbc.274.36.25455).
20. Kreuger J, Kjellen L. 2012 Heparan sulfate biosynthesis: regulation and variability. J. Histochem. Cytochem. 60, 898-907. (doi:10.1369/0022155412464972).
21. Rudd TR, Yates EA. 2012 A highly efficient tree structure for the biosynthesis of heparan sulfate accounts for the commonly observed disaccharides and suggests a mechanism for domain synthesis. Mol. Biosyst. 8, 1499-1506. (doi:10.1039/c2mb25019e).
22. Bain LJ, Feldman RA. 2003 Altered expression of sulfotransferases, glucuronosyltransferases and mrp transporters in FVB/mrp12/2 mice. Xenobiotica 33, 1173-1183. (doi:10.1080/00498250310001609138).
23. Lamanna WC, Frese MA, Balleininger M, Dierks T. 2008 Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J. Biol. Chem. 283, 27724-27735. (doi:10.1074/jbc.M802130200).
24. Turnbull J, Powell A, Guimond S. 2001 Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11, 75-82. (doi:10.1016/S0962-8924(00)01897-3).
25. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE. 1994 Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J. Biol. Chem. 269, 18881-18890.
26. Kraemer PM, Tobey RA. 1972 Cell-cycle dependent desquamation of heparan sulfate from the cell surface. J. Cell Biol. 55, 713-717. (doi:10.1083/jcb.55.3.713).
27. Blair OC, Sartorelli AC. 1984 Incorporation of 35Ssulfate and 3H-glucosamine into heparan and chondroitin sulfates during the cell cycle of B16-F10 cells. Cytometry 5, 281-288. (doi:10.1002/cyto.990050311).
28. Porcionatto MA, Pinto CR, Dietrich CP, Nader HB. 1994 Heparan sulfate proteoglycan and control of cell proliferation: enhanced synthesis induced by phorbol ester (PMA) during G(1)-phase. Braz. J. Med. Biol. Res. 27, 2185-2190.
29. Porcionatto MA, Moreira CR, Lotfi CF, Armelin HA, Dietrich CP, Nader HB. 1998 Stimulation of heparan sulfate proteoglycan synthesis and secretion during G1 phase induced by growth factors and PMA. J. Cell. Biochem. 70, 563-572. (doi:10.1002/(SICI)1097-4644(19980915)70:4, 563::AIDJCB12.3.0.CO;2-I).
30. Kayitmazer AB, Seeman D, Minsky BB, Dubin PL, Xu Y. 2013 Protein-polyelectrolyte interactions. Soft Matter 9, 2553-2583. (doi:10.1039/c2sm27002a).
31. Mulloy B, Forster MJ. 2000 Conformation and dynamics of heparin and heparan sulfate. Glycobiology 10, 1147-1156. (doi:10.1093/glycob/10.11.1147).
32. Nunes QM, Mournetas V, Lane B, Sutton R, Fernig DG, Vasieva O. 2013 The heparin-binding protein interactome in pancreatic diseases. Pancreatology 13, 598-604. (doi:10.1016/j.pan.2013.08.004).
33. Ori A, Wilkinson MC, Fernig DG. 2008 The heparanome and regulation of cell function: structures, functions and challenges. Front. Biosci. 13, 4309-4338. (doi:10.2741/3007).
34. Ori A, Wilkinson MC, Fernig DG. 2011 A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J. Biol. Chem. 286, 19892-19904. (doi:10.1074/jbc.M111.228114)
35. Powell AK, Yates EA, Fernig DG, Turnbull JE. 2004 Interactions of heparin/heparan sulfate with proteins: Appraisal of structural factors and experimental approaches. Glycobiology 14, R17-R30. (doi:10.1093/glycob/cwh051).
36. Xu D, Esko JD. 2014 Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83, 129-157. (doi:10.1146/annurev-biochem-060713-035314).
37. Kreuger J, Spillmann D, Li JP, Lindahl U. 2006 Interactions between heparan sulfate and proteins: The concept of specificity. J. Cell Biol. 174, 323-327. (doi:10.1083/jcb.200604035).
38. Gallagher JT. 2001 Heparan sulfate: growth control with a restricted sequence menu. J. Clin. Invest. 108, 357-361. (doi:10.1172/JCI13713).
39. Capila I, Linhardt RJ. 2002 Heparin-protein interactions. Angew. Chem. 41, 391-412. (doi:10.1002/1521-3773(20020201)41:3, 390::aidanie390.3.0.co;2-b).
40. Lindahl U, Li JP. 2009 Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell. Mol. Biol. 276, 105-159. (doi:10.1016/S1937-6448(09)76003-4).
41. Nugent MA, Zaia J, Spencer JL. 2013 Heparan sulfate-protein binding specificity. Biochemistry (Mosc). 78, 726-735. (doi:10.1134/S0006297913070055).
42. Perez S, Mulloy B. 2005 Prospects for glycoinformatics. Curr. Opin. Struct. Biol. 15, 517-524. (doi:10.1016/j.sbi.2005.08.005).
43. Gambarini AG, Miyamoto CA, Lima GA, Nader HB, Dietrich CP. 1993 Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate. Mol. Cell. Biochem. 124, 121-129. (doi:10.1007/BF00929204).
44. Kinsella L, Chen HL, Smith JA, Rudland PS, Fernig DG. 1998 Interactions of putative heparin-binding domains of basic fibroblast growth factor and its receptor, FGFR-1, with heparin using synthetic peptides. Glycoconj. J. 15, 419-422. (doi:10.1023/A:1006986104865).
45. Rahmoune H, Chen HL, Gallagher JT, Rudland PS, Fernig DG. 1998 Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J. Biol. Chem. 273, 7303-7310. (doi:10.1074/jbc.273.13.7303).
46. Mason K, Meikle P, Hopwood J, Fuller M. 2014 Distribution of heparan sulfate oligosaccharides in murine mucopolysaccharidosis type IIIA. Metabolites 4, 1088-1100. (doi:10.3390/metabo4041088).
47. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. 2005 In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl Acad. Sci. USA 102, 6473-6477. (doi:10.1073/pnas.0502287102).
48. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. 2004 Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl Cancer Inst. 96, 1219-1230. (doi:10.1093/jnci/djh230).
49. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R. 2006 Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int. J. Cancer 118, 1609-1617. (doi:10.1002/ijc.21552).
50. Gonzalez-Iglesias R, Pajares MA, Ocal C, Espinosa JC, Oesch B, Gasset M. 2002 Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J. Mol. Biol. 319, 527-540. (doi:10.1016/S0022-2836(02)00341-8).
51. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ. 1995 Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch. Biochem. Biophys. 323, 279-287. (doi:10.1006/abbi.1995.9963).
52. Sterner E et al. 2014 Fibroblast growth factor-based signaling through synthetic heparan sulfate blocks copolymers studied using high cell density threedimensional cell printing. J. Biol. Chem. 289, 9754-9765. (doi:10.1074/jbc.M113.546937).
53. Holman J, Skidmore MA, Rudd TR, Yates EA. 2010 The latent ampholytic nature of glycosaminoglycan (GAG) oligosaccharides facilitates their separation by isoelectric focusing. Anal. Methods 2, 1550-1554. (doi:10.1039/c0ay00340a).
54. Huang R, Liu J, Sharp JS. 2013 An approach for separation and complete structural sequencing of heparin/heparan sulfate-like oligosaccharides. Anal. Chem. 85, 5787-5795. (doi:10.1021/ac400439a).
55. Wei W, Miller RL, Leary JA. 2013 Method development and analysis of free HS and HS in proteoglycans from pre- And postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes. Anal. Chem. 85, 5917-5923. (doi:10.1021/ac400690g).
56. Ucakturk E, Cai C, Li L, Li G, Zhang F, Linhardt RJ. 2014 Capillary electrophoresis for total glycosaminoglycan analysis. Anal. Bioanal. Chem. 406, 4617-4626. (doi:10.1007/s00216-014-7859-8).
57. Inoue Y, Nagasawa K. 1976 Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr. Res. 46, 87-95. (doi:10.1016/S0008-6215(00)83533-8).
58. Rej RN, Ludwig-Baxter KG, Perlin AS. 1991 Sulfation of some chemically-modified heparins. Formation of a 3-sulfate analog of heparin. Carbohydr. Res. 210, 299-310. (doi:10.1016/0008-6215(91)80130-F).
59. Yates EA, Santini F, Guerrini M, Naggi A, Torri G, Casu B. 1996 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr. Res. 294, 15-27. (doi:10.1016/S0008-6215(96)00213-3).
60. Paredes-Gamero EJ et al. 2012 Chemical reduction of carboxyl groups in heparin abolishes its vasodilatory activity. J. Cell. Biochem. 113, 1359-1367. (doi:10.1002/jcb.24008).
61. Powell AK, Ahmed YA, Yates EA, Turnbull JE. 2010 Generating heparan sulfate saccharide libraries for glycomics applications. Nat. Protoc. 5, 821-833. (doi:10.1038/nprot.2010.17).
62. Uniewicz KA, Ori A, Ahmed YA, Yates EA, Fernig DG. 2014 Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars. PeerJ. 2, e461. (doi:10.7717/peerj.461).
63. Kreuger J, Prydz K, Pettersson RF, Lindahl U, Salmivirta M. 1999 Characterization of fibroblast growth factor 1 binding heparan sulfate domain. Glycobiology 9, 723-729. (doi:10.1093/glycob/9.7.723).
64. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U. 2001 Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J. Biol. Chem. 276, 30744-30752. (doi:10.1074/jbc.M102628200).
65. Maccarana M, Casu B, Lindahl U. 1993 Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268, 23898-23905. (doi:10.1007/bf01209909).
66. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. 1992 Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J. Biol. Chem. 267, 10337-10341.
67. Turnbull JE, Gallagher JT. 1993 Heparan sulphate: functional role as a modulator of fibroblast growth factor activity. Biochem. Soc. Trans. 21, 477-482.
68. Guerrini M et al. 2002 Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1. Biochem. Biophys. Res. Commun. 292, 222-230. (doi:10.1006/bbrc.2002.6634).
69. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. 1985 Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 24, 6723-6729. (doi:10.1021/bi00344a063).
70. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. 1987 Contribution of 3-O- And 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 26, 6454-6461. (doi:10.1021/bi00394a024).
71. Esko JD, Lindahl U. 2001 Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173. (doi:10.1172/JCI200113530).
72. Chavante SF, Brito AS, Lima M, Yates E, Nader H, Guerrini M, Torri G, Bisio A. 2014 A heparin-like glycosaminoglycan from shrimp containing high levels of 3-O-sulfated D-glucosamine groups in an unusual trisaccharide sequence. Carbohydr. Res. 390, 59-66. (doi:10.1016/j.carres.2014.03.002).
73. Lima MA et al. 2013 Antithrombin stabilisation by sulfated carbohydrates correlates with anticoagulant activity. Med. Chem. Commun. 4, 870-873. (doi:10.1039/c3md00048f ).
74. Guerrini M et al. 2013 An unusual antithrombinbinding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence. Biochem. J. 449, 343-351. (doi:10.1042/BJ20121309).
75. Guerrini M, Guglieri S, Beccati D, Torri G, Viskov C, Mourier P. 2006 Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem. J. 399, 191-198. (doi:10.1042/BJ20060656).
76. Guerrini M et al. 2008 Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J. Biol. Chem. 283, 26 662-26 675. (doi:10.1074/jbc.M801102200).
77. Guerrini M, Mourier PA, Torri G, Viskov C. 2014 Antithrombin-binding oligosaccharides: structural diversities in a unique function? Glycoconj. J. 31, 409-416. (doi:10.1007/s10719-014-9543-9).
78. Viskov C et al. 2013 Heparin dodecasaccharide containing two antithrombin-binding pentasaccharides: structural features and biological properties. J. Biol. Chem. 288, 25895-25907. (doi:10.1074/jbc.M113.485268).
79. Henry BL, Connell J, Liang A, Krishnasamy C, Desai UR. 2009 Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function. J. Biol. Chem. 284, 20897-20908. (doi:10.1074/jbc.M109.013359).
80. Johnson DJ, Huntington JA. 2003 Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 42, 8712-8719. (doi:10.1021/bi034524y).
81. Mosier PD, Krishnasamy C, Kellogg GE, Desai UR. 2012 On the specificity of heparin/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different. PLoS ONE 7, e48632. (doi:10.1371/journal.pone.0048632).
82. Toth L, Fekete A, Balogh G, Bereczky Z, Komaromi I. 2014 Dynamic properties of the native free antithrombin from molecular dynamics simulations: computational evidence for solvent-exposed Arg393 side chain. J. Biomol. Struct. Dyn. 8, 1-14.
83. Powell AK, Fernig DG, Turnbull JE. 2002 Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. J. Biol. Chem. 277, 28554-28563. (doi:10.1074/jbc.M111754200).
84. Rudd TR et al. 2010 Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org. Biomol. Chem. 8, 5390-5397. (doi:10.1039/c0ob00246a).
85. Ramachandra R et al. 2014 Brittlestars contain highly sulfated chondroitin sulfates/dermatan sulfates that promote fibroblast growth factor 2- induced cell signaling. Glycobiology 24, 195-207. (doi:10.1093/glycob/cwt100).
86. Xu R et al. 2012 Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity. J. Biol. Chem. 287, 40061-40073. (doi:10.1074/jbc.M112.398826).
87. Chang Z, Meyer K, Rapraeger AC, Friedl A. 2000 Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J. 14, 137-144.
88. Allen BL, Rapraeger AC. 2003 Spatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assembly. J. Cell. Biol. 163, 637-648. (doi:10.1083/jcb.200307053).
89. Zhang Z, Verheyden JM, Hassell JA, Sun X. 2009 FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Dev. Cell 16, 607-613. (doi:10.1016/j.devcel.2009.02.008).
90. Jastrebova N, Vanwildemeersch M, Lindahl U, Spillmann D. 2010 Heparan sulfate domain organization and sulfation modulate FGF-induced cell signaling. J. Biol. Chem. 285, 26842-26851. (doi:10.1074/jbc.M109.093542).
91. Yates EA, Guimond SE, Turnbull JE. 2004 Highly diverse heparan sulfate analogue libraries: providing access to expanded areas of sequence space for bioactivity screening. J. Med. Chem. 47, 277-280. (doi:10.1021/jm0309755).
92. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D. 2002 Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J. Biol. Chem. 277, 2444-2453. (doi:10.1074/jbc.M108540200).
93. Zhang H, Vutskits L, Pepper MS, Kiss JZ. 2003 VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. J. Cell Biol. 163, 1375-1384. (doi:10.1083/jcb.200308040).
94. Duchesne L, Tissot B, Rudd TR, Dell A, Fernig DG. 2006 N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate coreceptor binding. J. Biol. Chem. 281, 27178- 27189. (doi:10.1074/jbc.M601248200).
95. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. 1996 Heparin structure and interactions with basic fibroblast growth factor. Science 271, 1116-1120. (doi:10.1126/science.271.5252.1116).
96. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. 2000 Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407, 1029-1034. (doi:10.1038/35039551).
97. Schlessinger J et al. 2000 Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-750. (doi:10.1016/S1097-2765(00)00073-3).
98. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. 1993 Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 268, 23906-23914.
99. Naimy H, Buczek-Thomas JA, Nugent MA, Leymarie N, Zaia J. 2011 Highly sulfated nonreducing endderived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions. J. Biol. Chem. 286, 19311-19319. (doi:10.1074/jbc.M110.204693).
100. Munoz-Garcia JC et al. 2014 Importance of the polarity of the glycosaminoglycan chain on the interaction with FGF-1. Glycobiology 24, 1004-1009. (doi:10.1093/glycob/cwu071).
101. Liu J, Linhardt RJ. 2014 Chemoenzymatic synthesis of heparan sulfate and heparin. Nat. Prod. Rep. 31, 1676-1685. (doi:10.1039/C4NP00076E).
102. Xu Y, Pempe EH, Liu J. 2012 Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities. J. Biol. Chem. 287, 29054-29061. (doi:10.1074/jbc.M112.358523).
103. Hu YP et al. 2012 Divergent synthesis of 48 heparan sulfate-based disaccharides and probing the specific sugar-fibroblast growth factor-1 interaction. J. Am. Chem. Soc. 134, 20722-20727. (doi:10.1021/ja3090065).
104. Chavante SF, Santos EA, Oliveira FW, Guerrini M, Torri G, Casu B, Dietrich CP, Nader HB. 2000 A novel heparan sulphate with high degree of N-sulphation and high heparin cofactor-II activity from the brine shrimp Artemia franciscana. Int. J. Biol. Macromol. 27, 49-57. (doi:10.1016/S0141-8130(99)00114-2).
105. Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI. 1997 Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 95, 118-124. (doi:10.1161/01.CIR.95.1.118).
106. Dietrich CP et al. 1999 Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochim. Biophys. Acta 1428, 273-283. (doi:10.1016/S0304-4165(99)00087-2).
107. Guimond SE, Turnbull JE. 1999 Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr. Biol. 9, 1343-1346. (doi:10.1016/S0960-9822(00)80060-3).
108. Pye DA, Vives RR, Hyde P, Gallagher JT. 2000 Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 10, 1183-1192. (doi:10.1093/glycob/10.11.1183).
109. Walker A, Turnbull JE, Gallagher JT. 1994 Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J. Biol. Chem. 269, 931-935.
110. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB. 2009 Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. Anais da Academia Brasileira de Ciencias 81, 409-429. (doi:10.1590/S0001-37652009000300007).
111. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. 2007 The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J. Biotechnol. 129, 290-307. (doi:10.1016/j.jbiotec.2007.01.022).
112. Snel B, Lehmann G, Bork P, Huynen MA. 2000 STRING: A web-server to retrieve and display the repeatedly occurring neighbourhood of a gene Nucleic Acids Res. 28, 3442-3444. (doi:10.1093/nar/28.18.3442).
113. Straus AH, Sant'anna OA, Nader HB, Dietrich CP. 1984 An inverse relationship between heparin content and antibody response in genetically selected mice. Sex effect and evidence of a polygenic control for skin heparin concentration. Biochem. J. 220, 625-630.
114. Mulloy B. 2005 The specificity of interactions between proteins and sulfated polysaccharides. Anais da Academia Brasileira de Ciencias 77, 651- 664. (doi:10.1590/S0001-37652005000400007).
115. Rudd TR, Yates EA. 2010 Conformational degeneracy restricts the effective information content of heparan sulfate. Mol. Biosyst. 6, 902-908. (doi:10.1039/b923519a).
116. Chu CL, Goerges AL, Nugent MA. 2005 Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry 44, 12203-12213. (doi:10.1021/bi050241p).
117. Forsten-Williams K, Chu CL, Fannon M, Buczek- Thomas JA, Nugent MA. 2008 Control of growth factor networks by heparan sulfate proteoglycans. Ann. Biomed. Eng. 36, 2134-2148. (doi:10.1007/s10439-008-9575-z).
118. Ornitz DM et al. 1996 Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271, 15292-15297. (doi:10.1074/jbc.271.25.15292).
119. Xu R, Rudd TR, Hughes AJ, Siligardi G, Fernig DG, Yates EA. 2013 Analysis of the fibroblast growth factor receptor (FGFR) signalling network with heparin as coreceptor: evidence for the expansion of the core FGFR signalling network. FEBS J. 280, 2260-2270. (doi:10.1111/febs.12201).
120. Peysselon F, Ricard-Blum S. 2014 Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol. 35, 73-81. (doi:10.1016/j.matbio.2013.11.001).
121. Chiodelli P, Bugatti A, Urbinati C, Rusnati M. 2015 Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules 20, 6342-6388. (doi:10.3390/molecules20046342).
122. Chen Y, Scully M, Dawson G, Goodwin C, Xia M, Lu X, Kakkar A. 2013 Perturbation of the heparin/heparinsulfate interactome of human breast cancer cells modulates pro-tumourigenic effects associated with PI3 K/Akt and MAPK/ERK signalling. Thromb. Haemost. 109, 1148-1157. (doi:10.1160/TH12-12-0935).
123. Seyrek E, Dubin P. 2010 Glycosaminoglycans as polyelectrolytes. Adv. Colloid Interface Sci. 158, 119-129. (doi:10.1016/j.cis.2010.03.001).
124. Hattori T, Bat-Aldar S, Kato R, Bohidar HB, Dubin PL. 2005 Characterization of polyanion-protein complexes by frontal analysis continuous capillary electrophoresis and small angle neutron scattering: effect of polyanion flexibility. Anal. Biochem. 342, 229-236. (doi:10.1016/j.ab.2005.03.043).
125. Seyrek E, Dubin PL, Henriksen J. 2007 Nonspecific electrostatic binding characteristics of the heparin-antithrombin interaction. Biopolymers 86, 249-259. (doi:10.1002/bip.20731).
126. Seyrek E, Dubin PL, Tribet C, Gamble EA. 2003 Ionic strength dependence of protein-polyelectrolyte interactions. Biomacromolecules 4, 273-282. (doi:10.1021/bm025664a).
127. Hart DJ, Speight RE, Cooper MA, Sutherland JD, Blackburn JM. 1999 The salt dependence of DNA recognition by NF-kB p50: A detailed kinetic analysis of the effects on affinity and specificity. Nucleic Acids Res. 27, 1063-1069. (doi:10.1093/nar/27.4.1063).
128. Desai UR, Petitou M, Bjork I, Olson ST. 1998 Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites. Biochemistry 37, 13033-13041. (doi:10.1021/bi981426h).
129. Thompson LD, Pantoliano MW, Springer BA. 1994 Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33, 3831-3840. (doi:10.1021/bi00179a006).
130. Heidarieh M, Maragheh MG, Shamami MA, Behgar M, Ziaei F, Akbari Z. 2013 Evaluate of heavy metal concentration in shrimp (Penaeus semisulcatus) and crab (Portunus pelagicus) with INAA method. SpringerPlus 2, 72. (doi:10.1186/2193-1801-2-72).
131. Landt M, Hortin GL, Smith CH, McClellan A, Scott MG. 1994 Interference in ionized calcium measurements by heparin salts. Clin. Chem. 40, 565-570.
132. Sepulveda-Diaz JE et al. 2015 HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology. Brain 138, 1339-1354. (doi:10.1093/brain/awv056).
133. Griffith MJ, Beavers G, Kingdon HS, Lundblad RL. 1980 Effect of monovalent cations on the heparinenhanced antithrombin III/thrombin reaction. Thromb. Res. 17, 29-39. (doi:10.1016/0049-3848(80)90291-1).
134. Alessandri G, Raju K, Gullino PM. 1984 Angiogenesis in vivo and selective mobilization of capillary endothelium in vitro by heparin-copper complex. Microcirc. Endothel. Lymphatics 1, 329-346.
135. Finney L et al. 2007 X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc. Natl Acad. Sci. USA 104, 2247-2252. (doi:10.1073/pnas.0607238104).
136. Rabenstein DL, Robert JM, Peng J. 1995 Multinuclear magnetic resonance studies of the interaction of inorganic cations with heparin. Carbohydr. Res. 278, 239-256. (doi:10.1016/0008-6215(95)00263-4).
137. Grant D, Long WF, Williamson FB. 1992 A potentiometric titration study of the interaction of heparin with metal cations. Biochem. J. 285, 477-480.
138. Manning GS. 1978 The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides. Q. Rev. Biophys. 11, 179-246. (doi:10.1017/S0033583500002031).
139. Ander P, Lubas W. 1981 Sodium ion diffusionin aqueous salt-free heparin solutions. Macromolecules 14, 1058-1061. (doi:10.1021/ma50005a032).
140. Tivant P, Turq P, Drifford M, Magdelenat H, Menez R. 1983 Effect of ionic strength on the diffusion coefficient of chondroitin sulfate and heparin measured by quasielastic light scattering. Biopolymers 22, 643-662. (doi:10.1002/bip.360220209).
141. Chevalier F, Angulo J, Lucas R, Nieto Pedro M, Martín-Lomas M. 2002 The heparin2Ca2 interaction: structure of the Ca2 binding site. Eur. J. Org. Chem. 2002, 2367-2376. (doi:10.1002/1099-0690(200207)2002:14, 2367::AID-EJOC2367.3.0.CO;2-K).
142. Rudd TR et al. 2007 Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives. Glycobiology 17, 983-993. (doi:10.1093/glycob/cwm062).
143. Solari V, Rudd TR, Guimond SE, Powell AK, Turnbull JE, Yates EA. 2015 Heparan sulfate phage display antibodies recognise epitopes defined by a combination of sugar sequence and cation binding. Org. Biomol. Chem. 13, 6066-6072. (doi:10.1039/C5OB00564G).
144. Hricovini M. 2011 Effect of solvent and counterions upon structure and NMR spin-spin coupling constants in heparin disaccharide. J. Phys. Chem. B 115, 1503-1511. (doi:10.1021/jp1098552).
145. Kan M, Wang F, To B, Gabriel JL, McKeehan WL. 1996 Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex. J. Biol. Chem. 271, 26143-26148. (doi:10.1074/jbc.271.42.26143).
146. Guimond SE et al. 2009 Cations modulate polysaccharide structure to determine FGF-FGFR signaling: A comparison of signaling and inhibitory polysaccharide interactions with FGF-1 in solution. Biochemistry 48, 4772-4779. (doi:10.1021/bi802318z).
147. Cordula CR et al. 2014 On the catalytic mechanism of polysaccharide lyases: evidence of His and Tyr involvement in heparin lysis by heparinase I and the role of Ca2. Mol. Biosyst. 10, 54-64. (doi:10.1039/C3MB70370C).
148. Capila I, Hernaiz MJ, Mo YD, Mealy TR, Campos B, Dedman JR, Linhardt RJ, Seaton BA. 2001 Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces. Structure 9, 57-64. (doi:10.1016/S0969-2126(00)00549-9).
149. Capila I, VanderNoot VA, Mealy TR, Seaton BA, Linhardt RJ. 1999 Interaction of heparin with annexin V. FEBS Lett. 446, 327-330. (doi:10.1016/S0014-5793(99)00245-8).
150. Horlacher T, Noti C, de-Paz JL, Bindschadler P, Hecht ML, Smith DF, Fukuda MN, Seeberger PH. 2011 Characterization of annexin A1 glycan binding reveals binding to highly sulfated glycans with preference for highly sulfated heparan sulfate and heparin. Biochemistry 50, 2650-2659. (doi:10.1021/bi101121a).
151. Young TN, Edelberg JM, Stack S, Pizzo SV. 1992 Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: The effects of ionic strength, divalent cations, and chloride. Arch. Biochem. Biophys. 296, 530-538. (doi:10.1016/0003-9861(92)90607-X).
152. Blake CCF, Koenig DF, Mair GA, North ACT, Phillips DC, Sarma VR. 1965 Structure of hen egg-white lysozyme: A three-dimensional Fourier synthesis at 2A° resolution. Nature 206, 757-761. (doi:10.1038/206757a0).
153. Holder GM et al. 2012 Fundamental differences in model cell-surface polysaccharides revealed by complementary optical and spectroscopic techniques. Soft Matter 8, 6521-6527. (doi:10.1039/c2sm25239b).
154. Rudd TR et al. 2008 Site-specific interactions of copper(II) ions with heparin revealed with complementary (SRCD, NMR, FTIR and EPR) spectroscopic techniques. Carbohydr. Res. 343, 2184-2193. (doi:10.1016/j.carres.2007.12.019).
155. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. 1998 Heparan sulfate oligosaccharides require 6-Osulfation for promotion of basic fibroblast growth factor mitogenic activity. J. Biol. Chem. 273, 22936-22942. (doi:10.1074/jbc.273.36.22936).
156. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimenez-Gallego G, Lindahl U. 2002 Biosynthetic oligosaccharide libraries for identification of proteinbinding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J. Biol. Chem. 277, 30567-30573.
157. Kreuger J, Jemth P, Sanders-Lindberg E, Eliahu L, Ron D, Basilico C, Salmivirta M, Lindahl U. 2005 Fibroblast growth factors share binding sites in heparan sulphate. Biochem. J. 389, 145-150. (doi:10.1042/BJ20042129).
158. Catlow K, Deakin JA, Delehedde M, Fernig DG, Gallagher JT, Pavao MS, Lyon M. 2003 Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. Biochem. Soc. Trans. 31, 352-353. (doi:10.1042/BST0310352).
159. Hagner-McWhirter A, Li JP, Oscarson S, Lindahl U. 2004 Irreversible glucuronyl C5-epimerization in the biosynthesis of heparan sulfate. J. Biol. Chem. 279, 14631-14638. (doi:10.1074/jbc.M313760200).
160. Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, Lounis B, Fernig DG. 2012 Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol. 10, e1001361. (doi:10.1371/journal.pbio.1001361).
161. De-Paz JL, Noti C, Bohm F, Werner S, Seeberger PH. 2007 Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers. Chem. Biol. 14, 879-887. (doi:10.1016/j.chembiol.2007.07.007).
162. Speight MO, Griffith MJ. 1983 Calcium inhibits the heparin-catalyzed antithrombin III/thrombin reaction by decreasing the apparent binding affinity of heparin for thrombin. Arch. Biochem. Biophys. 225, 958-963. (doi:10.1016/0003-9861(83)90111-X).